P&G Health September profit rises 26% as revenue gains 18%

Procter & Gamble Health Limited reported net profit of Rs 110.56 crore for the three months ended September 30, 2026, up 26% from Rs 88.54 crore a year earlier. P&G Health’s revenue from operations rose 18% to Rs 382.49 crore, while profit before tax increased to Rs 150.05 crore from Rs 119.02 crore.

How did P&G Health perform in the September 2026 quarter?

P&G Health increased revenue from operations by Rs 57.57 crore to Rs 382.49 crore in the three months ended September 30, 2026, from Rs 324.92 crore in the corresponding three months ended September 30, 2025. Other income declined to Rs 3.89 crore from Rs 4.95 crore, taking total income to Rs 386.38 crore, compared with Rs 329.87 crore a year earlier.

P&G Health’s profit before exceptional items and tax rose to Rs 150.05 crore from Rs 119.02 crore in the year-earlier quarter. The company reported no exceptional item in either September quarter. Total tax expense was Rs 39.49 crore in the 2026 quarter, including current tax of Rs 35.95 crore, deferred-tax charge of Rs 2.59 crore and Rs 0.95 crore relating to earlier periods.

P&G Health reported basic and diluted earnings per share of Rs 67.18 for the September 2026 quarter, compared with Rs 53.34 in the corresponding 2025 quarter. Paid-up equity share capital remained Rs 16.60 crore, with a face value of Rs 10 a share. Other comprehensive income was a Rs 0.95 crore loss, compared with a Rs 2.42 crore gain a year earlier.

What changed from the June 2026 quarter?

P&G Health’s September-quarter revenue from operations was Rs 382.49 crore, compared with Rs 363.71 crore in the preceding three months ended June 30, 2026. Total income rose from Rs 367.59 crore in June to Rs 386.38 crore in September, while profit before exceptional items and tax increased from Rs 97.32 crore to Rs 150.05 crore.

The June 2026 comparison includes a separately disclosed exceptional gain of Rs 31.80 crore. P&G Health sold its Worli office premises during the quarter ended June 30, 2026 for Rs 33.34 crore, when its carrying amount was Rs 1.54 crore. The resulting Rs 31.80 crore gain was recorded as an exceptional item in that June-quarter result.

P&G Health’s reported net profit was Rs 96.15 crore in the June 2026 quarter, including the property-sale gain, compared with Rs 110.56 crore in September. Basic and diluted earnings per share after exceptional items were Rs 57.92 in June and Rs 67.18 in September; June earnings per share before exceptional items were Rs 38.77. Reported sequential profit therefore includes the effect of the June property transaction.

What do P&G Health’s six-month results show?

P&G Health reported revenue from operations of Rs 746.20 crore for the six months ended September 30, 2026, up from Rs 663.66 crore in the corresponding six months of 2025. Total income increased to Rs 753.97 crore from Rs 672.64 crore, while profit before exceptional items and tax rose to Rs 247.37 crore from Rs 207.13 crore.

P&G Health’s six-month profit before tax was Rs 279.17 crore, including the Rs 31.80 crore June exceptional gain, compared with Rs 207.13 crore in the prior-year period. Net profit reached Rs 207.02 crore, against Rs 154.72 crore a year earlier. Earnings per share after exceptional items were Rs 125.09, compared with Rs 93.21, while earnings per share before exceptional items were Rs 105.94.

P&G Health’s total tax expense for the six-month period was Rs 72.15 crore, compared with Rs 53.11 crore in the corresponding 2025 period. Other comprehensive income was a Rs 0.64 crore loss in the 2026 half year, against a Rs 1.77 crore gain a year earlier. Total comprehensive income was therefore Rs 206.38 crore, compared with Rs 156.49 crore.

What do P&G Health’s balance sheet and cash flows show?

P&G Health had total assets of Rs 1,014.59 crore as of September 30, 2026, compared with Rs 841.35 crore at March 31, 2026. Cash and cash equivalents increased to Rs 322.86 crore from Rs 177.24 crore, while trade receivables rose to Rs 175.80 crore from Rs 164.26 crore. Inventories were Rs 136.89 crore, compared with Rs 136.65 crore at the financial year-end.

P&G Health’s total equity rose to Rs 658.05 crore at September 30, 2026 from Rs 524.55 crore at March 31, 2026. Other equity was Rs 641.45 crore, compared with Rs 507.95 crore, while total liabilities increased to Rs 356.54 crore from Rs 316.80 crore. Current liabilities were Rs 296.85 crore and non-current liabilities were Rs 59.69 crore at September 30.

P&G Health generated Rs 190.86 crore of operating cash flow in the six months ended September 30, 2026, compared with Rs 172.23 crore in the prior-year period. Investing activities generated Rs 31.73 crore, against Rs 1.41 crore, including Rs 33.64 crore of proceeds from disposal of property, plant and equipment and assets held for sale. Financing activities used Rs 76.97 crore, including dividend payments of Rs 74.70 crore.

Which business segment does P&G Health report?

P&G Health identifies Pharmaceuticals as its single primary reportable segment under Indian Accounting Standard 108, Operating Segments. It therefore did not provide a separate revenue, profit or asset split by product category or additional operating segment for the quarter ended September 30, 2026 or the six-month period.

P&G Health also stated that it had no subsidiary, associate or joint venture as of September 30, 2026. The Audit Committee reviewed, and the Board approved, the unaudited results on November 2, 2026. Haribhakti & Co. LLP’s limited review report said nothing had come to its attention that caused it to believe the financial statement contained a material misstatement.

Conclusion

P&G Health recorded faster growth in net profit than revenue in the September 2026 quarter, with net profit rising 26% to Rs 110.56 crore and revenue rising 18% to Rs 382.49 crore. The six-month net profit of Rs 207.02 crore included the Rs 31.80 crore exceptional gain from the June 2026 sale of the Worli office premises.

The unresolved disclosure point is the absence of product-level or business-line figures because P&G Health reports Pharmaceuticals as its sole segment. Future financial statements will be needed to show whether revenue and profit before exceptional items continue to change without another separately disclosed property-sale gain.